What is the projected market valuation for the Hereditary Angioedema Treatment Market in 2035?

The projected market valuation for the Hereditary Angioedema Treatment Market in 2035 is expected to reach 4.375 USD Billion. Read More

What was the market valuation for the Hereditary Angioedema Treatment Market in 2024?

The market valuation for the Hereditary Angioedema Treatment Market in 2024 was 2.374 USD Billion. Read More

What is the expected CAGR for the Hereditary Angioedema Treatment Market from 2025 to 2035?

The expected CAGR for the Hereditary Angioedema Treatment Market during the forecast period 2025 - 2035 is 5.71%. Read More

Which companies are considered key players in the Hereditary Angioedema Treatment Market?

Key players in the Hereditary Angioedema Treatment Market include Shire, CSL Behring, Takeda Pharmaceutical Company Limited, and others. Read More

What segment of the Hereditary Angioedema Treatment Market had the highest valuation in 2024?

In 2024, the segment of C1 Esterase Inhibitor Replacement Therapy had the highest valuation at 0.95 USD Billion. Read More

How does the market valuation for Oral administration compare to other routes in 2024?

In 2024, the market valuation for Oral administration was 0.95 USD Billion, which is higher than both Intravenous and Subcutaneous routes. Read More

What is the market valuation for the Pediatric age group segment in 2024?

The market valuation for the Pediatric age group segment in 2024 was 0.474 USD Billion. Read More

What is the projected growth for the Congenital Hereditary Angioedema diagnosis type by 2035?

The projected growth for the Congenital Hereditary Angioedema diagnosis type is expected to reach 2.125 USD Billion by 2035. Read More

Which route of administration is expected to show significant growth by 2035?

Both Intravenous and Subcutaneous routes are expected to show significant growth, with valuations projected to reach 1.325 USD Billion by 2035. Read More

What is the market valuation for Blood Plasma Derived Therapies in 2024?

The market valuation for Blood Plasma Derived Therapies in 2024 was 0.3 USD Billion. Read More

Hereditary Angioedema Treatment Market

ID: MRFR/HC/35781-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

Hereditary Angioedema Treatment Market Research Report: Size, Share, Trend Analysis By Types of Treatment (C1 Esterase Inhibitor Replacement Therapy, Bradykinin B2 Receptor Antagonists, Recombinant C1 Esterase Inhibitor, Blood Plasma Derived Therapies), By Route of Administration (Intravenous, Subcutaneous, Oral), By Patient Age Group (Pediatric, Adult, Geriatric), By Diagnosis Type (Acquired Hereditary Angioedema, Congenital Hereditary Angioedema, Idiopathic Angioedema) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Hereditary Angioedema Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Type (USD Billion)
4.1.1 C1 Esterase Inhibitor Replacement Therapy
4.1.2 Bradykinin B2 Receptor Antagonists
4.1.3 Recombinant C1 Esterase Inhibitor
4.1.4 Blood Plasma Derived Therapies
4.2 Healthcare, BY Route of Administration (USD Billion)
4.2.1 Intravenous
4.2.2 Subcutaneous
4.2.3 Oral
4.3 Healthcare, BY Patient Age Group (USD Billion)
4.3.1 Pediatric
4.3.2 Adult
4.3.3 Geriatric
4.4 Healthcare, BY Diagnosis Type (USD Billion)
4.4.1 Acquired Hereditary Angioedema
4.4.2 Congenital Hereditary Angioedema
4.4.3 Idiopathic Angioedema
4.5 Healthcare, BY Region (USD Billion)
4.5.1 North America
4.5.1.1 US
4.5.1.2 Canada
4.5.2 Europe
4.5.2.1 Germany
4.5.2.2 UK
4.5.2.3 France
4.5.2.4 Russia
4.5.2.5 Italy
4.5.2.6 Spain
4.5.2.7 Rest of Europe
4.5.3 APAC
4.5.3.1 China
4.5.3.2 India
4.5.3.3 Japan
4.5.3.4 South Korea
4.5.3.5 Malaysia
4.5.3.6 Thailand
4.5.3.7 Indonesia
4.5.3.8 Rest of APAC
4.5.4 South America
4.5.4.1 Brazil
4.5.4.2 Mexico
4.5.4.3 Argentina
4.5.4.4 Rest of South America
4.5.5 MEA
4.5.5.1 GCC Countries
4.5.5.2 South Africa
4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Shire (GB)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 CSL Behring (AU)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Takeda Pharmaceutical Company Limited (JP)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Pharming Group (NL)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 BioCryst Pharmaceuticals (US)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Sobi (SE)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Ferring Pharmaceuticals (CH)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Vertex Pharmaceuticals (US)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 Grifols (ES)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY TYPE
6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.5 US MARKET ANALYSIS BY PATIENT AGE GROUP
6.6 US MARKET ANALYSIS BY DIAGNOSIS TYPE
6.7 CANADA MARKET ANALYSIS BY TYPE
6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.9 CANADA MARKET ANALYSIS BY PATIENT AGE GROUP
6.10 CANADA MARKET ANALYSIS BY DIAGNOSIS TYPE
6.11 EUROPE MARKET ANALYSIS
6.12 GERMANY MARKET ANALYSIS BY TYPE
6.13 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.14 GERMANY MARKET ANALYSIS BY PATIENT AGE GROUP
6.15 GERMANY MARKET ANALYSIS BY DIAGNOSIS TYPE
6.16 UK MARKET ANALYSIS BY TYPE
6.17 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.18 UK MARKET ANALYSIS BY PATIENT AGE GROUP
6.19 UK MARKET ANALYSIS BY DIAGNOSIS TYPE
6.20 FRANCE MARKET ANALYSIS BY TYPE
6.21 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.22 FRANCE MARKET ANALYSIS BY PATIENT AGE GROUP
6.23 FRANCE MARKET ANALYSIS BY DIAGNOSIS TYPE
6.24 RUSSIA MARKET ANALYSIS BY TYPE
6.25 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.26 RUSSIA MARKET ANALYSIS BY PATIENT AGE GROUP
6.27 RUSSIA MARKET ANALYSIS BY DIAGNOSIS TYPE
6.28 ITALY MARKET ANALYSIS BY TYPE
6.29 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.30 ITALY MARKET ANALYSIS BY PATIENT AGE GROUP
6.31 ITALY MARKET ANALYSIS BY DIAGNOSIS TYPE
6.32 SPAIN MARKET ANALYSIS BY TYPE
6.33 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.34 SPAIN MARKET ANALYSIS BY PATIENT AGE GROUP
6.35 SPAIN MARKET ANALYSIS BY DIAGNOSIS TYPE
6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
6.37 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.38 REST OF EUROPE MARKET ANALYSIS BY PATIENT AGE GROUP
6.39 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS TYPE
6.40 APAC MARKET ANALYSIS
6.41 CHINA MARKET ANALYSIS BY TYPE
6.42 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.43 CHINA MARKET ANALYSIS BY PATIENT AGE GROUP
6.44 CHINA MARKET ANALYSIS BY DIAGNOSIS TYPE
6.45 INDIA MARKET ANALYSIS BY TYPE
6.46 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.47 INDIA MARKET ANALYSIS BY PATIENT AGE GROUP
6.48 INDIA MARKET ANALYSIS BY DIAGNOSIS TYPE
6.49 JAPAN MARKET ANALYSIS BY TYPE
6.50 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.51 JAPAN MARKET ANALYSIS BY PATIENT AGE GROUP
6.52 JAPAN MARKET ANALYSIS BY DIAGNOSIS TYPE
6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
6.54 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.55 SOUTH KOREA MARKET ANALYSIS BY PATIENT AGE GROUP
6.56 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS TYPE
6.57 MALAYSIA MARKET ANALYSIS BY TYPE
6.58 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.59 MALAYSIA MARKET ANALYSIS BY PATIENT AGE GROUP
6.60 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS TYPE
6.61 THAILAND MARKET ANALYSIS BY TYPE
6.62 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.63 THAILAND MARKET ANALYSIS BY PATIENT AGE GROUP
6.64 THAILAND MARKET ANALYSIS BY DIAGNOSIS TYPE
6.65 INDONESIA MARKET ANALYSIS BY TYPE
6.66 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.67 INDONESIA MARKET ANALYSIS BY PATIENT AGE GROUP
6.68 INDONESIA MARKET ANALYSIS BY DIAGNOSIS TYPE
6.69 REST OF APAC MARKET ANALYSIS BY TYPE
6.70 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.71 REST OF APAC MARKET ANALYSIS BY PATIENT AGE GROUP
6.72 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS TYPE
6.73 SOUTH AMERICA MARKET ANALYSIS
6.74 BRAZIL MARKET ANALYSIS BY TYPE
6.75 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.76 BRAZIL MARKET ANALYSIS BY PATIENT AGE GROUP
6.77 BRAZIL MARKET ANALYSIS BY DIAGNOSIS TYPE
6.78 MEXICO MARKET ANALYSIS BY TYPE
6.79 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.80 MEXICO MARKET ANALYSIS BY PATIENT AGE GROUP
6.81 MEXICO MARKET ANALYSIS BY DIAGNOSIS TYPE
6.82 ARGENTINA MARKET ANALYSIS BY TYPE
6.83 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.84 ARGENTINA MARKET ANALYSIS BY PATIENT AGE GROUP
6.85 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS TYPE
6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT AGE GROUP
6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS TYPE
6.90 MEA MARKET ANALYSIS
6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
6.92 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.93 GCC COUNTRIES MARKET ANALYSIS BY PATIENT AGE GROUP
6.94 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS TYPE
6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
6.96 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.97 SOUTH AFRICA MARKET ANALYSIS BY PATIENT AGE GROUP
6.98 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS TYPE
6.99 REST OF MEA MARKET ANALYSIS BY TYPE
6.100 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.101 REST OF MEA MARKET ANALYSIS BY PATIENT AGE GROUP
6.102 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS TYPE
6.103 KEY BUYING CRITERIA OF HEALTHCARE
6.104 RESEARCH PROCESS OF MRFR
6.105 DRO ANALYSIS OF HEALTHCARE
6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
6.111 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
6.112 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
6.113 HEALTHCARE, BY PATIENT AGE GROUP, 2024 (% SHARE)
6.114 HEALTHCARE, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Billion)
6.115 HEALTHCARE, BY DIAGNOSIS TYPE, 2024 (% SHARE)
6.116 HEALTHCARE, BY DIAGNOSIS TYPE, 2024 TO 2035 (USD Billion)
6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY TYPE, 2025-2035 (USD Billion)
7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.2.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.2.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY TYPE, 2025-2035 (USD Billion)
7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.3.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.3.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY TYPE, 2025-2035 (USD Billion)
7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.4.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.4.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY TYPE, 2025-2035 (USD Billion)
7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.5.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.5.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY TYPE, 2025-2035 (USD Billion)
7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.6.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.6.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY TYPE, 2025-2035 (USD Billion)
7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.7.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.7.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY TYPE, 2025-2035 (USD Billion)
7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.8.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.8.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY TYPE, 2025-2035 (USD Billion)
7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.9.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.9.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY TYPE, 2025-2035 (USD Billion)
7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.10.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.10.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY TYPE, 2025-2035 (USD Billion)
7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.11.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.11.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY TYPE, 2025-2035 (USD Billion)
7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.12.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.12.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY TYPE, 2025-2035 (USD Billion)
7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.13.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.13.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY TYPE, 2025-2035 (USD Billion)
7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.14.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.14.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY TYPE, 2025-2035 (USD Billion)
7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.15.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.15.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY TYPE, 2025-2035 (USD Billion)
7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.16.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.16.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY TYPE, 2025-2035 (USD Billion)
7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.17.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.17.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY TYPE, 2025-2035 (USD Billion)
7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.18.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.18.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY TYPE, 2025-2035 (USD Billion)
7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.19.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.19.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY TYPE, 2025-2035 (USD Billion)
7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.20.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.20.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY TYPE, 2025-2035 (USD Billion)
7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.21.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.21.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY TYPE, 2025-2035 (USD Billion)
7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.22.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.22.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY TYPE, 2025-2035 (USD Billion)
7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.23.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.23.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY TYPE, 2025-2035 (USD Billion)
7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.24.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.24.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY TYPE, 2025-2035 (USD Billion)
7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.25.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.25.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY TYPE, 2025-2035 (USD Billion)
7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.26.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.26.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY TYPE, 2025-2035 (USD Billion)
7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.27.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.27.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY TYPE, 2025-2035 (USD Billion)
7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.28.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.28.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY TYPE, 2025-2035 (USD Billion)
7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.29.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.29.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY TYPE, 2025-2035 (USD Billion)
7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.30.3 BY PATIENT AGE GROUP, 2025-2035 (USD Billion)
7.30.4 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

C1 Esterase Inhibitor Replacement Therapy
Bradykinin B2 Receptor Antagonists
Recombinant C1 Esterase Inhibitor
Blood Plasma Derived Therapies

Healthcare By Route of Administration (USD Billion, 2025-2035)

Intravenous
Subcutaneous
Oral

Healthcare By Patient Age Group (USD Billion, 2025-2035)

Pediatric
Adult
Geriatric

Healthcare By Diagnosis Type (USD Billion, 2025-2035)

Acquired Hereditary Angioedema
Congenital Hereditary Angioedema
Idiopathic Angioedema

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓